Literature DB >> 27927596

Quantification of muscle pathology in infantile Pompe disease.

Anne Schänzer1, Ann-Kathrin Kaiser2, Christian Mühlfeld3, Martin Kulessa2, Werner Paulus4, Harald von Pein5, Marianne Rohrbach6, Lara Viergutz2, Eugen Mengel7, Thorsten Marquardt8, Bernd Neubauer9, Till Acker2, Andreas Hahn9.   

Abstract

The effects of enzyme replacement therapy (ERT) in infantile Pompe disease are variable, necessitating the identification of biomarkers to assess the severity of disease and response to ERT. The aims of this study were to investigate whether quantification of muscle pathology in infantile Pompe disease prior to and during ERT is feasible at the light microscope, and to develop a score that summarizes the degree of muscle pathology in a comprehensive manner from PAS-stained resin sections alone. We, therefore, determined glycogen load, extent of muscle fibre disruption, and amount of autophagic vacuoles in resin-embedded muscle biopsy specimens from 11 infantile Pompe patients and 2 with early childhood phenotype by quantitative methods, correlated the findings with ultrastructural analyses, compared PAS-stained resin sections with conventional PAS-stained cryosections, and related the quantified degree of muscle damage from infantile patients to the effects of ERT. Comparison of electron and light microscopic findings demonstrated that important alterations of skeletal muscle morphology can also be depicted by examining PAS stained resin sections. Infantile patients with good response to ERT had lower muscle pathology score values prior to and during ERT than those with moderate and poor response, but the number of tissue samples available for evaluation was limited. These findings suggest that quantification of muscle pathology by analysing PAS stained resin sections is in principle feasible and useful to monitor disease progression and therapy response. These results have to be validated by investigating a larger group of patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acid maltase deficiency; Autophagy; Enzyme replacement therapy; Glycogen storage disease type II; Lysosomal storage disease; Pompe disease

Mesh:

Substances:

Year:  2016        PMID: 27927596     DOI: 10.1016/j.nmd.2016.10.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

Review 1.  Long-term outcome and unmet needs in infantile-onset Pompe disease.

Authors:  Andreas Hahn; Anne Schänzer
Journal:  Ann Transl Med       Date:  2019-07

2.  Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.

Authors:  Claudia Nuñez-Peralta; Jorge Alonso-Pérez; Jaume Llauger; Sonia Segovia; Paula Montesinos; Izaskun Belmonte; Irene Pedrosa; Elena Montiel; Alicia Alonso-Jiménez; Javier Sánchez-González; Antonio Martínez-Noguera; Isabel Illa; Jordi Díaz-Manera
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-03-04       Impact factor: 12.910

3.  Letter to the Editors: Concerning "Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state" by Takashi et al. and Letter to the Editors by Ortolano et al.

Authors:  Anne Schänzer; Kerstin Giese; Lara Viergutz; Andreas Hahn
Journal:  Mol Genet Metab Rep       Date:  2017-05-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.